Tag:
Novavax
Latest Headlines
Latest Headlines
Bird flu vaccine hits the clinic
Novavax saw a climb in its share value on the announcement that it has started enrollment of a Phase I clinical trial of its A/H5N1 vaccine to prevent bird flu.
Novavax gets a new CEO
Rockville-based Novavax has announced that Stanley Erck, its former executive chairman, is taking over as the company's new CEO. Prior to joining Novavax, Erck was CEO of Iomai Corporation, which
Interview: Novavax's CEO discusses HHS flu vaccine funding
Earlier this week, the HHS doubled down on new vaccine technology. The government granted Maryland-based Novavax a contract worth up to $179.1 million, while Cranbury, NJ's VaxInnate picked up a
Novavax, VaxInnate win $215M to develop better pandemic vaccines
The feds drive to whip up a bigger, faster supply of flu vaccine to fight pandemics has triggered a pair of new contracts initially totaling $215 million for Novavax and VaxInnate. Novavax shares
FDA lifts hold on Novavax RSV vaccine trial
Shares of Novavax ($NVAX) surged this morning on the news that the FDA has lifted its clinical hold on a Phase I study of an experimental RSV vaccine. Back in November the biotech reported that it
Novavax reports mild response in PhII seasonal flu trial
Shares of Novavax were buoyed slightly by the news that its mid-stage trial of a closely-watched seasonal flu vaccine demonstrated significant immunogenicity against one of three flu strains among
Novavax shares surge on promising H1N1 trial data
Shares of Novavax (NVAX) spiked as high as 16 percent on Wednesday after the vaccine developer reported some encouraging results from its clinical trial in Mexico for its experimental H1N1 vaccine.
Novavax, ROVI end talks over flu vax
In a terse statement, Novavax said today that it's halted negotiations in its pursuit of the previously announced collaboration with ROVI Pharmaceuticals to develop Novavax's virus-like-particle
Novavax buoyed by progress on two vaccine fronts
Novavax reported a pair of key milestones this week in its quest to introduce a new vaccine technology to the world. Researchers reported that the developer's closely-watched trial of a new swine flu
Red-hot Novavax negotiating vax tech transfers
Back in early April Novavax's stock was trading for a meager 52 cents a share. Before the bell this morning it hit $6.01. And CEO Rahul Singhvi clearly believes that the vaccine-maker, which is
